Perspective Therapeutics, Inc. (CATX) Stock Price & Analysis
Perspective Therapeutics, Inc. (CATX) closed at USD 2.34 on Thursday, October 15, 2026, up 4.46% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.24; the Oct 15, 2026 session ranged USD 2.23–2.37 on volume of 1,184,315 shares. Market capitalization is $267.11M, with a 52-week range of USD 1.96–6.16 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CATX.md
Key facts (CATX)
- Analysts: Buy (mean 1.94 on a 1–5 scale) (16 analysts), mean target USD 12.29 (range 5–18).
- Total return with dividends: 1Y -50.7% vs S&P 500 +18.1%; 5Y -62.3% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.25, revenue estimate $52K.
Analysts (CATX)
Consensus Buy (mean 1.94 on a 1–5 scale), 16 analysts; mean target USD 12.29 (low 5, high 18).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | BTIG | Reiterated | Buy | $14 |
| 2026-09-18 | William Blair | Initiated | Outperform | |
| 2026-09-15 | Wedbush | Reiterated | Outperform | $11 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $11 |
| 2026-08-14 | B of A Securities | Target lowered | Neutral | $6 → $5 |
| 2026-08-11 | Piper Sandler | Target lowered | Overweight | $16 → $14 |
Total return (dividends reinvested) (CATX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -50.7% | -62.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -50.9% | -17.7% |
| Volatility (annualized) | 98.9% | 98.8% |
| Max drawdown | -60.4% (Feb 2026→Oct 2026) | -90.1% (Apr 2024→Mar 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 2.34 |
|---|---|
| Change | ▲ 4.46% (up) |
| Previous Close | USD 2.24 |
| Open | USD 2.27 |
| Day Range | USD 2.23 – 2.37 |
| 52-Week Range | USD 1.96 – 6.16 |
| Volume | 1,184,315 shares |
| Market Cap | $267.11M |
| Exchange | ASE |
Technical Analysis (CATX)
Nexqual's technical model rates CATX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.58 (neutral) |
| vs SMA50 | Below (USD 2.89) |
| MACD | -0.15 (negative) |
Analyst Ratings (CATX)
Wall Street analysts rate CATX "Buy" based on 16 analysts, with a mean price target of USD 12.29 (range USD 5–18), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 12.29 |
| High Target | USD 18 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (CATX)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $51,790 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.22 vs est -0.27 ▲ beat |
| 2026-03-31 | USD -0.25 vs est -0.32 ▲ beat |
| 2025-12-31 | USD -0.51 vs est -0.34 ▼ miss |
| 2025-09-30 | USD -0.35 vs est -0.32 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (CATX)
| Total Revenue | $409,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -72.10% |
| Gross Margin | +0.00% |
| Operating Margin | -36120.99% |
| Profit Margin | +0.00% |
| ROE | -39.57% |
| Debt / Equity | 0.01 |
| Current Ratio | 6.61 |
| Total Cash | $236.88M |
| Total Debt | $3.96M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (CATX)
Nexqual rates Perspective Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -39% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $237M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$82M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -40%, ROA -22.3% |
Ownership (CATX)
| Insider Ownership | +8.23% |
|---|---|
| Institutional Ownership | +86.02% |
| Shares Outstanding | 114.15M |
| Float | 70.82M |
| Short % of Float | +17.34% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (CATX)
Perspective Therapeutics, Inc. is led by Johan M. Spoor (age 53), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Johan M. Spoor (age 53) |
|---|---|
| CFO & Principal Financial Officer | Joel David Sendek (age 58) |
| Executive Vice President of Operations | Shane Cobb |
| Vice President of Investor Relations | Annie J. Cheng (age 49) |
| Executive Vice President of Brachytherapy | Andrew Bright |
Major Backers & Investors (CATX)
Notable institutional backers of Perspective Therapeutics, Inc. include TCG Crossover Management, LLC, Commodore Capital Lp, Avidity Partners Management, LP, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 6.93% |
| Commodore Capital Lp | 5.55% |
| Avidity Partners Management, LP | 5.52% |
| Millennium Management | 4.3% |
| Affinity Asset Advisors, Llc | 3.69% |
| Citadel | 3.33% |
| Spruce Street Capital LP | 3.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.35% |
| Vanguard Group | 7.96% |
| State Street | 5.3% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt